IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS
Japanese Encephalitis Vaccine Inactivated JE-VAX® Sanofi Pasteur	**Children 1 through 2 years of age:** First: 0.5 mL SC Second: 0.5 mL SC 7 days later Third: 0.5 mL SC 30 days after first dose* **Persons 3 years of age and over:** First: 1.0 mL SC Second: 1.0 mL SC 7 days later Third: 1.0 mL SC 30 days after first dose* * An abbreviated schedule of 0, 7, and 14 days may be used when the longer schedule is impractical because of time constraints. The last dose should be given at least 10 days before travel to ensure an adequate immune response and access to health care in the event of delayed adverse reactions. (See Comments and Contraindications)	0.5 mL SC after 2 years 1.0 mL SC after 2 years	IXIARO will be the only vaccine for JE available in the United States. JE-VAX is no longer being produced. The remaining doses of JE-VAX are being distributed in a limited quantity monthly to providers who have previously ordered this vaccine from Sanofi. At present, JE-VAX is the only vaccine licensed for use in children aged 1 through 16 years. Safety and effectiveness of IXIARO in a pediatric population (<17 years of age) has not been established. Studies are in process. **Indications:** Japanese encephalitis vaccination is indicated only for persons spending 1 month or longer in endemic areas (which include China, Japan, Korea, and Eastern Russia), especially rural areas, during the transmission season. Depending on the epidemic circumstances, vaccine should be considered for persons spending less than 30 days whose activities, such as extensive outdoor activities in rural areas, place them at particularly high risk for exposure. **Special Instructions:** Advise travelers that the current U.S. and international advisories should be consulted regarding prevalence of Japanese encephalitis in specific locations. Counsel persons traveling to epidemic and endemic areas that the vaccine may not fully protect everyone who gets it and that personal precautions should be taken to reduce exposure to mosquito bites (adequate clothing, use of repellents, mosquito nets). For IXIARO give the vaccine recipient the required vaccination information sheet found with the package insert. CDC also has a Vaccine Information Statement on Japanese Encephalitis Vaccine for vaccine recipients. Provide an opportunity to discuss any questions or concerns. **Adverse Reactions:** **JE-VAX:** Moderate frequency of local and mild systemic side effects. Injection site tenderness, redness, swelling and other local effects have been reported in about 20% of vaccinees (< 1% to 31%). Systemic side effects principally fever, headache, malaise, rash, and other reactions, such as chills, dizziness, myalgia, nausea, vomiting, and abdominal pain have been reported in approximately 10% of vaccinees. However, more severe systemic side effects which can include angioedema of the extremities, face, and oropharynx, especially of the lips, and hypertension, can occur up to 17 days (usually within 10 days) of receipt of vaccine (About 60 per 10,000 people vaccinated have had allergic reactions to JE vaccine.). Other severe problems, such as seizures or nervous system problems have been reported; these are rare (probably less than 1 per 50,000 people vaccinated). **IXAIRO:** The most common (≥ 10%) systemic adverse events observed in clinical trials were headache and myalgia. The most common (≥ 10%) local reactions after vaccine administration were pain and tenderness. Nausea, skin rash, fatigue, flu-like illness, and fever may also occur. **Contraindications and Precautions:** **JE-VAX:** Anaphylactic reaction to previous dose of vaccine, or severe hypersensitivity to any component of the vaccine, especially proteins of rodent or neural origin. Vaccine contains thimersol. **IXAIRO;** Anaphylactic reaction to previous dose of vaccine, or severe hypersensitivity to any component of the vaccine, including protamine sulfate. This vaccine should be used during pregnancy only if clearly needed.
Japanese Encephalitis Vaccine Inactivated, Adsorbed IXIARO ® Intercell Biomedical	**Persons 17 years of age and over:** First: 0.5 mL IM Second: 0.5 mL IM 28 days later* *Immunization series should be completed at least 1 week prior to potential exposure to JEV.	Not established	